What Can a PET/CAT Scan Diagnose?
A PET scan (positron emission tomography) is a metabolic imaging technique that can diagnose and stage various cancers, detect metastases, differentiate benign from malignant lesions, evaluate treatment response, and identify inflammatory/infectious conditions—it works by detecting increased glucose metabolism in abnormal cells using the radiotracer FDG (fluorodeoxyglucose).
How PET Scanning Works
PET imaging exploits the fact that cancer cells have dramatically higher glucose metabolism than normal cells. The radiotracer FDG is taken up by cells just like glucose but becomes trapped after phosphorylation, accumulating in metabolically active tissues. This allows PET to provide "metabolic" information that complements the anatomic detail from CT scans 1.
Primary Clinical Applications
Cancer Diagnosis and Staging
Lung Cancer:
- Differentiating benign from malignant lung nodules ≥1 cm with 96% sensitivity and 79% specificity 1
- Staging non-small cell lung cancer (NSCLC) with superior accuracy compared to CT alone
- Detecting unexpected distant metastases in 5-29% of patients after negative conventional staging 1
- The detection rate increases with stage: 8% in stage I, 18% in stage II, and 24% in stage III 1
Important caveat: PET has limitations with subcentimeter lesions, bronchoalveolar carcinomas, and well-differentiated adenocarcinomas, which may show little FDG uptake 1, 2.
Lymph Node Staging
PET demonstrates excellent negative predictive value for mediastinal lymph nodes—patients with PET-negative mediastinum can proceed directly to surgery without invasive staging procedures, provided: (1) the primary tumor shows sufficient FDG uptake, (2) there's no central tumor obscuring N2 disease, and (3) a dedicated PET camera is used 1.
However, positive findings require tissue confirmation due to false-positives from anthracosilicosis, infection, or granulomatous disease 1.
Other Malignancies
Lymphoma:
- Recommended for staging and response evaluation in Hodgkin's and diffuse large B-cell lymphoma 3
- Identifies patients not needing additional radiotherapy
- Predicts progression-free survival 3
Colorectal Cancer:
- Useful when CT/MRI findings are equivocal for liver metastases 4
- Recommended for suspected recurrence with rising tumor markers but negative CT 5, 3
- Not recommended for routine surveillance 4
Melanoma:
- All stage 3 patients should receive PET/CT staging—it's the most sensitive method for detecting distant metastases 3
- Detects unrecognized metastases leading to management changes in 10-19% of patients 3
Head and Neck Cancer:
- Identifies 30% of primary tumors not detected by conventional means in cases of unknown primary 3
PET/CT Fusion Advantages
Combined PET/CT is superior to either modality alone, particularly for:
- Improved T3/T4 staging in lung cancer
- Better tumor delineation in atelectasis
- More accurate localization of metabolic abnormalities 6
Non-Oncologic Applications
Inflammatory and Infectious Diseases
Large Vessel Vasculitis:
- Sensitivity 82-84%, specificity 79-87% for diagnosis 7
- Useful for treatment monitoring, though with lower specificity (71%) 7
Cardiac Sarcoidosis:
- Sensitivity 84%, specificity 82-83% when proper myocardial suppression protocols are used 7
- Superior to other imaging when patients are not on anti-inflammatory therapy
- Enables risk stratification for major cardiovascular events 7
Critical Limitations to Remember
False-Negatives Occur With:
- Lesions <1 cm (below spatial resolution of 7-10 mm) 2
- Low-grade malignancies (carcinoid tumors, adenocarcinoma in situ) 2
- Mucinous tumors 5
False-Positives Occur With:
- Active infections
- Granulomatous diseases (tuberculosis, sarcoidosis)
- Inflammatory conditions
- Recent surgery or radiation 1
Practical Clinical Algorithm
For solitary pulmonary nodules:
- If PET-negative and low clinical suspicion → follow with CT at 3,6,12, and 24 months 1
- If PET-positive → proceed to tissue diagnosis or resection 1
For mediastinal staging in lung cancer:
- If PET-negative → proceed directly to surgery (if criteria met) 1
- If PET-positive → mandatory mediastinoscopy for confirmation 1
For suspected metastatic disease:
- PET/CT changes staging in 27-62% of NSCLC patients 1
- Changes management in 25-52% of cases, mainly from curative to palliative intent 1
Veterinary Applications (Cats)
While the evidence is limited, PET/CT has been successfully used in cats for:
- Staging thyroid carcinoma 8
- Guiding treatment in lymphoma 9
- Measuring tumor volume in oral squamous cell carcinoma 10
The technique shows promise but lacks established veterinary guidelines 11.